CFHR ELISA Kits
Complement Factor H-Related (CFHR) proteins are part of the complement system, which plays a crucial role in innate immunity and the regulation of inflammatory responses. The CFHR family consists of several homologous proteins (e.g., CFHR1, CFHR2, CFHR3, etc.), which are involved in modulating complement activity and have been implicated in various diseases, including atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD), and autoimmune conditions.
Content of CFHR ELISA Kits
A typical CFHR ELISA kit includes:
- Enzyme conjugate: Usually streptavidin-HRP (horseradish peroxidase) for catalyzing a colorimetric reaction.
- Substrate solution: TMB (3,3’,5,5’-Tetramethylbenzidine) for developing a measurable signal upon reaction with HRP.
- Stop solution: Typically sulfuric acid or another acid to halt the enzyme reaction and stabilize the color for reading.
- Assay and wash buffers: For sample preparation, dilution, and thorough washing steps that reduce background noise and ensure high assay specificity.
Application of CFHR ELISA Kits
CFHR ELISA kits have numerous applications in research and clinical studies, including:
- Autoimmune and inflammatory diseases: CFHR proteins modulate immune responses, making them relevant in studying autoimmune diseases such as systemic lupus erythematosus (SLE). Elevated or altered CFHR levels can signify an imbalance in complement regulation.
- Cancer research: Changes in the expression of CFHR proteins have been observed in certain cancers, suggesting a role in tumor immunity and progression. ELISA kits facilitate the measurement of CFHR proteins to support research into tumor microenvironments and immune evasion mechanisms.
- Biomarker discovery: CFHR levels can serve as biomarkers for identifying disease risk, progression, and response to treatment in various immune and inflammatory disorders.
The use of CFHR ELISA kits provides reliable, specific, and sensitive quantification of CFHR proteins, offering essential data for understanding complement-related mechanisms and developing targeted therapeutic strategies.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|